Inhibition of the CDK9-cyclin T1 protein-protein interaction as a new approach against triple-negative breast cancer.

Cyclin-dependent kinase 9 (CDK9) activity is correlated with worse outcomes of triple-negative breast cancer (TNBC) patients. The heterodimer between CDK9 with cyclin T1 is essential for maintaining the active state of the kinase and targeting this protein-protein interaction (PPI) may offer promising avenues for selective CDK9 inhibition. Herein, we designed and generated a library of metal complexes bearing the 7-chloro-2-phenylquinoline CˆN ligand and tested their activity against the CDK9-cyclin T1 PPI. Complex bound to CDK9 an enthalpically-driven binding mode, leading to disruption of the CDK9-cyclin T1 interaction and . Importantly, complex showed promising anti-metastatic activity against TNBC allografts in mice and was comparably active compared to cisplatin. To our knowledge, is the first CDK9-cyclin T1 PPI inhibitor with anti-metastatic activity against TNBC. Complex could serve as a new platform for the future design of more efficacious kinase inhibitors against cancer, including TNBC.